Cargando…

OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome wherein small tumors secrete excess fibroblast growth factor 23 (FGF23) leading to hypophosphatemia, osteomalacia, bone pain, fractures, and muscle weakness. Burosumab is an anti-FGF23 monoclonal antibody approved for treatment of TI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carpenter, Thomas, Cimms, Tricia, Hetzer, Joel, Insogna, Karl, Kumar, Rajiv, Merritt II, J Lawrence, Miller, Paul, Peacock, Munro, Rauch, Frank, Stanciu, Irinel, Weber, Thomas, Jan De Beur, Suzanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Bone & Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624705/ http://dx.doi.org/10.1210/jendso/bvac150.394

Ejemplares similares

OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
por: Carpenter, Thomas O, et al.
Publicado: (2020)

OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome
por: Jan De Beur, Suzanne, et al.
Publicado: (2019)

Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)

Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing
por: Jan de Beur, Suzanne M., et al.
Publicado: (2021)

OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program
por: Carpenter, Thomas, et al.
Publicado: (2022)

SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
por: Murari, Keerti, et al.
Publicado: (2020)

Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report
por: Oe, Yuki, et al.
Publicado: (2021)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

PSAT218 Technetium 99m-Methyl Diphosphonate (99mTc MDP) Radioguided Surgery in Patient With Tumor-Induced Osteomalacia (TIO)
por: Khan, Sara A, et al.
Publicado: (2022)

SUN-525 Burosumab Experience In A UK Adolescent Population
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

SUN-523 XLH Outcome Data from One Centre Experience with Burosumab
por: Cheung, Moira, et al.
Publicado: (2019)

ODP083 Burosumab Treatment for Fibrous dysplasia/McCune-Albright Syndrome with Severe Spine Deformity
por: Sato, Tetsuhiko, et al.
Publicado: (2022)

SUN-524 Burosumab Initiation In A UK XLH Cohort: Real-World Use Resonates With Research Evidence
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Severe Osteomalacia and Fractures Secondary to Vitamin D Deficiency
por: Mathew, Justin, et al.
Publicado: (2021)

ODP125 Soft Bones in Crohn's: Tumor-induced osteomalacia and inflammatory bowel disease
por: Habbsa, Samima, et al.
Publicado: (2022)

MON-501 A Hemangioma Causing Tumor Induced Osteomalacia
por: Chinnakotla, Venkata Sai Bhavana, et al.
Publicado: (2019)

MON-502 It's Not Always Osteoporosis: FGF-23 Induced Osteomalacia
por: Bello Segura, Manuel, et al.
Publicado: (2019)

THU464 An Uncommon Case Of Adult-Onset Hypophosphatemic Osteomalacia
por: Lockhart, Paola M, et al.
Publicado: (2023)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019)

SAT-337 Ga-DOTATATE and Tumor Induced Osteomalacia: Finding the Culprit Lesion
por: Berman, Jessica, et al.
Publicado: (2020)

MON-352 When Osteoporosis Does Not Make Sense: Tumor-Induced Osteomalacia
por: Techathaveewat, Pawarid, et al.
Publicado: (2020)

Tumor Induced Osteomalacia - Long Term Medical Treatment When Surgery Is Risky
por: Levy, Shiri, et al.
Publicado: (2021)

Successful Medical Management of a Non-Localising Case of Tumour-Induced Osteomalacia
por: Shan Hoong, Caroline Wei, et al.
Publicado: (2021)

OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials
por: Wolf, Myles, et al.
Publicado: (2019)

MON-500 A Case of Tumor-Induced Osteomalacia Caused by Metastatic Prostate Cancer
por: Rahman, Wedad, et al.
Publicado: (2019)

Tumor Induced Osteomalacia in Patients With Metastatic Prostate Cancer: Case Report and Literature Review
por: Khadilkar, Arjun, et al.
Publicado: (2021)

Diagnostic Dilemma of Elevated FGF23 in a Patient With Osteomalacia: A Case Report
por: Bulut, Aysegul, et al.
Publicado: (2021)

Sternal Phosphaturic Mesenchymal Tumor-Induced Osteomalacia, Diagnosis and Management: A Case Report
por: Adeyemo, Mopelola Adetola, et al.
Publicado: (2021)

MON-499 Tumor Induced Osteomalacia: (68)Ga-DOTATATE PET/CT Scan For Localization
por: Thangavelu, Thiyagarajan, et al.
Publicado: (2019)

SAT-385 A Normal FGF23 Does Not Preclude Tumor Induced Osteomalacia (TIO)
por: Nandam, Neeharika, et al.
Publicado: (2020)

MON-364 Severe Postoperative Encephalopathy in a Patient with Oncogenic Osteomalacia and Neurofibromatosis Type 1
por: Sarkar, Sauradeep, et al.
Publicado: (2020)

THU440 A Case Of Osteomalacia In A Young Adult Female With Premature Ovarian Insufficiency
por: Kasimoglu, Ismail Hakki, et al.
Publicado: (2023)

THU465 Significant Improvement In Bone Mineral Density Following Treatment For Tumor Induced Osteomalacia
por: McHan, Lara C, et al.
Publicado: (2023)

MON-504 Osteomalacia During Pregnancy: Are Preventive Measures Enough to Avoid Future Fractures and Fetal Complications?
por: Pujals Kury, Jean, et al.
Publicado: (2019)

MON-353 Tumor-Induced Osteomalacia from a Hypervascular Thoracic Paraspinal Mass: Challenges in Diagnosis and Management
por: Perez, Paola M, et al.
Publicado: (2020)

SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia
por: Gafni, Rachel Ilana, et al.
Publicado: (2020)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

PSAT223 A Delayed Diagnosis of Oncogenic Osteomalacia Presenting with Bone Pain, Muscle Weakness and Elevated Alkaline Phosphatase
por: Gastelum, Alheli Arce, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ii16q227nr86k2lbn2pdgfplqn